Metastatic Breast Cancer
Conditions
Brief summary
This study is a retrospective review aimed at evaluating the real-world outcomes and clinical efficacy of CDK4/6 inhibitors (such as Palbociclib, Ribociclib, or Abemaciclib) in patients diagnosed with metastatic luminal A and luminal B breast cancer. The study will assess how patients responded to these treatments based on their specific breast cancer subtype (Luminal A vs. Luminal B) by reviewing their medical records.
Detailed description
This is a retrospective, observational cohort study conducted at Sohag University Hospital\]. The study will include medical records of female patients diagnosed with metastatic Luminal A and Luminal B breast cancer who received CDK4/6 inhibitors as part of their treatment regimen between 2021 and 2026 Data will be collected regarding Patient demographics and baseline clinical characteristics. Pathological features (Hormone receptor status and Ki-67 levels to differentiate Luminal A and B). Treatment duration and response rates. Outcomes such as Progression-Free Survival (PFS) and Overall Survival (OS), as well as documented adverse effects. The primary objective is to compare the clinical outcomes and effectiveness of CDK4/6 inhibitors between the Luminal A and Luminal B metastatic breast cancer subgroups in a real-world setting.
Interventions
DRUGCDK4/6 inhibitors
Retrospective evaluation of patients who received standard clinical doses of CDK4/6 inhibitors as part of their treatment regimen for metastatic luminal A and luminal B breast cancer.
Sponsors
Sohag University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* patients who are more than 18 years old at time of diagnosis and less than 80 years * metastatic breast cancer luminal A and luminal B of either sex
Exclusion criteria
* patients diagnosed with double malignancy * patients with incomplete medical records * patients with organ failure
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| progression free survival | Up to 4 years أو From initiation of CDK4/6 inhibitor therapy to disease progression or death, up to 4 years. | Progression-free survival is defined as the time from initiation of CDK4/6 inhibitor therapy until documented disease progression or death from any cause. |
| Progression-Free Survival (PFS) | From the date of therapy initiation up to 4 yrs | PFS is defined as the time from the initiation of CDK4/6 inhibitor therapy to the date of documented disease progression or death from any cause, whichever occurs first. |
Countries
Egypt
Outcome results
None listed